Trial Profile

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of LY3537021 When Combined With GLP-1 Receptor Agonist in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Oct 2023 Results (n=32) assessing the safety and tolerability profile of LY3537021 (LY) in combination with liraglutide, in order to evaluate potential mitigation of liraglutide-related gastrointestinal adverse events presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
28 Feb 2023 Status changed from active, no longer recruiting to completed.
22 Nov 2022 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com